EGFR and lung cancer: Moreover, a study evaluating the detection of EGFR gene mutations from different biofluids, including PE, ascites, pericardial effusion, and CSF, has revealed a higher detection rate and sensitivity of tumor-specific mutations in biofluid-supernatant-free DNA in comparison with biofluid sediment tumor cells and plasma-free DNA samples in patients with lung cancer [187].